Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,810 | -4,687 | -2,922 | -865 | -4,307 |
| Depreciation Amortization | 8,812 | 8,118 | 8,499 | 3,845 | 4,365 |
| Income taxes - deferred | -23 | -398 | -2,861 | -1,584 | -279 |
| Accounts receivable | 3,105 | 468 | -2,792 | 196 | 566 |
| Accounts payable and accrued liabilities | 1,491 | -2,048 | N/A | -918 | -2,413 |
| Other Working Capital | 4,106 | 42 | -1,675 | -3,811 | -41 |
| Other Operating Activity | -350 | 6,550 | 4,635 | 4,194 | 7,492 |
| Operating Cash Flow | $9,331 | $8,045 | $2,884 | $1,057 | $5,383 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,152 | -1,216 | -986 | -878 | -1,445 |
| Net Acquisitions | N/A | 1,002 | -52,794 | N/A | 1,417 |
| Purchase Sale Intangibles | -250 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -250 | -15 | -16 | -39 | -34 |
| Investing Cash Flow | $-1,402 | $-229 | $-53,796 | $-917 | $-62 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 61,315 | 4,300 | 70,700 | 2,750 | 4,000 |
| Debt Repayment | -66,912 | -11,703 | -20,198 | -4,702 | -9,050 |
| Common Stock Issued | 669 | -221 | 4,557 | 160 | 182 |
| Other Financing Activity | -3,039 | 0 | -2,006 | 0 | 0 |
| Financing Cash Flow | $-7,967 | $-7,624 | $53,053 | $-1,792 | $-4,868 |
| Exchange Rate Effect | 20 | -30 | 299 | 1,789 | -1,601 |
| Beginning Cash Position | 8,335 | 8,173 | 5,733 | 5,596 | 6,744 |
| End Cash Position | 8,317 | 8,335 | 8,173 | 5,733 | 5,596 |
| Net Cash Flow | $-18 | $162 | $2,440 | $137 | $-1,148 |
| Free Cash Flow | |||||
| Operating Cash Flow | 9,331 | 8,045 | 2,884 | 1,057 | 5,383 |
| Capital Expenditure | -1,152 | -1,216 | -986 | -890 | -1,445 |
| Free Cash Flow | 8,179 | 6,829 | 1,898 | 167 | 3,938 |